Background Anticoagulation therapy is used in several conditions to prevent or treat
thromboembolism. Recently, new oral anticoagulants have been introduced as alternatives …

Background Non–vitamin K antagonist oral anticoagulants are used to prevent
thromboembolism in patients with atrial fibrillation. The T‐TAS “Total Thrombus‐formation …

Background: Measuring anti-Xa activity (AXA) has been reported as useful for predicting
future risk of hemorrhagic and ischemic events in stroke patients taking direct factor Xa …

Background: Chromogenic anti-factor Xa activity (AXA) assay is reported to be the most
appropriate method to measure the pharmacodynamics of apixaban, but the distribution of …

Introduction: The prompt assessment and the reversal of direct oral anticoagulants (DOACs)
are urgent matters in the emergency care setting. Thus, we planned to elucidate the …

Background Little is known about physiological anticoagulation effects via antithrombin III
(AT III) and protein C/S (PC/PS) in patients using new oral anticoagulants (NOACs). Methods …

Horses with inflammatory and infectious disorders are often treated with injectable heparin
anticoagulants to prevent thrombotic complications. In humans, a new class of direct oral …

Background Information on apixaban anticoagulant activity is required to prevent major
bleeding or thrombosis during its use. Methods We enrolled 194 patients with nonvalvular …

Clinical demand for the prompt assessment of the activity of direct-acting factor Xa inhibitors
in the emergency care setting is increasing. In the present study, we examined whether …

Methods and Results: Thrombus formation was evaluated with the Total Thrombus-formation
Analysis System (T-TAS®) using 2 types of microchips in 145 patients with stable coronary …